Effects of Cytochrome P450 3A4 Inhibitors – Ketoconazole and Erythromycin – on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions

Publication: Clin Pharmacokinet
Software: GastroPlus®

Objective

To assess the effect of strong and moderate cytochrome P450 (CYP) 3A4 inhibition on exposure of bitopertin, a glycine reuptake inhibitor primarily metabolized by CYP3A4, and to compare the results with predictions based on physiologically based pharmacokinetic (PBPK) modelling.